Outcome of aspirin treatment of antiphospholipid antibody-positive patients Kathleen M. O’Neil Clinical Trials Report 04 February 2009 Pages: 1 - 2
The use of opioids in the treatment of osteoarthritis: When, why, and how? Jeremy L. R. GoodwinJan J. KraemerZahid H. Bajwa OriginalPaper 04 February 2009 Pages: 5 - 14
The biomechanics of osteoarthritis: Implications for therapy Joel A. BlockNajia Shakoor OriginalPaper 04 February 2009 Pages: 15 - 22
WNT signaling in osteoarthritis and osteoporosis: What is the biological significance for the clinician? Liesbet LodewyckxRik J. U. Lories OriginalPaper 04 February 2009 Pages: 23 - 30
Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs Matthias Hermann OriginalPaper 04 February 2009 Pages: 31 - 35
Aspirin and acetaminophen: Should they be available over the counter? Kay BruneBurkhard HinzIvan Otterness OriginalPaper 04 February 2009 Pages: 36 - 40
Antiphospholipid antibodies in rheumatoid arthritis: Identifying the dominoes Debbie A. GladdEwa Olech OriginalPaper 04 February 2009 Pages: 43 - 51
Renal manifestations of the antiphospholipid syndrome David D’Cruz OriginalPaper 04 February 2009 Pages: 52 - 60
Atherosclerosis in autoimmune diseases Eiji MatsuuraKazuko KobayashiLuis R. Lopez OriginalPaper 04 February 2009 Pages: 61 - 69
Neonatal effects of maternal antiphospholipid syndrome Angela TincaniChiara Biasini RebaioliMario Motta OriginalPaper 04 February 2009 Pages: 70 - 76
Mechanisms of antiphospholipid-induced thrombosis: Effects on the protein C system Denis WahlAurélie MembreThomas Lecompte OriginalPaper 04 February 2009 Pages: 77 - 81